Rasmus Kidmose, European Business Development Director at CRB explores the benefits of working with global partners, no matter your location.
Project owners in the life sciences industry are uniquely familiar with that old adage, “The only constant is change.” Facing the pressures of Covid-19 and ignited by new technologies and research advances, the industry has undergone immense transformation over the last eighteen months. Cell and gene therapy innovators are particularly notable agents of change; they raised $19.9 billion in 2020, exceeding 2019’s investment by more than 200%. The European Commission recognised this momentum in its recent EU Pharmaceutical Strategy, which aims to drive further competitiveness and innovation in the industry. Change isn’t coming—it’s already here, and it’s transforming life science research in the EU.
To keep up with this pace, the industry’s assumptions about capital project delivery must change. In particular, the notion that working with a regional Architecture, Engineering and Construction (AEC) partner is the most effective way to balance cost, quality, and speed when developing the facilities to support the industry’s continuous growth.